Nuclear Medicine and Biology
Volume 35, Issue 2 , Pages 219-225 , February 2008

Effects of increasing doses of samarium-153-ethylenediaminetetramethylene phosphonate on axial and appendicular skeletal growth in juvenile rabbits

  • Stephanie C. Essman

      Affiliations

    • Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri-Columbia, Columbia, MO 65211
    • Corresponding Author InformationCorresponding author. Tel.: +1 573 882 7821; fax: +1 573 884 5444.
    • ,
  • Michael R. Lewis

      Affiliations

    • Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri-Columbia, Columbia, MO 65211
    • Department of Radiology, University of Missouri-Columbia, Columbia, MO 65211
    • Nuclear Science and Engineering Institute, University of Missouri-Columbia, Columbia, MO 65211
    • Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201
    • ,
  • Derek B. Fox

      Affiliations

    • Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri-Columbia, Columbia, MO 65211

Received 9 August 2007 ,Revised 12 November 2007 ,Accepted 13 November 2007.

References 

  1. Eifel PJ, Donaldson SS, Thomas PF. Response of growing bone to irradiation: a proposed late effects scoring system. Int J Radiat Oncol Biol Phys. 1995;31:1301–1307
  2. Melanotte PL, Follis RH. Early effects of x-irradiation on cartilage and bone. Am J Pathol. 1961;39:1–7
  3. Rutherford H, Dodd GD. Complications of radiation therapy: growing bone. Semin Roentgenol. 1974;9:15–27
  4. Probert JC, Parker BR. The effects of radiation therapy on bone growth. Radiology. 1975;114:155–162
  5. Parker RG, Berry HC. Late effects of therapeutic irradiation on the skeleton and bone marrow. Cancer. 1976;37:1162–1171
  6. Gonzalez DG, Breur K. Clinical data from irradiated growing long bones in children. Int J Radiat Oncol Biol Phys. 1983;9:841–846
  7. Ben-Josef E, Porter AT. Radioisotopes in the treatment of bone metastases. Ann Med. 1997;29:31–35
  8. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys. 1994;30:1187–1194
  9. Campa JA, Payne R. The management of intractable bone pain: a clinician's perspective. Semin Nucl Med. 1992;22:3–10
  10. Serafini AN. Systemic metabolic radiotherapy with samarium-153-EDTMP for the treatment of painful bone metastasis. Q J Nucl Med. 2001;45:91–99
  11. Janjan N. Bone metastasis: approaches to management. Semin Oncol. 2001;28:28–34
  12. Diener KM. Bisphosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm. 1996;53:1917–1927
  13. Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med. 1987;28:495–504
  14. Lattimer JC, Corwin LA, Stapleton J, et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP. J Nucl Med. 1990;31:1316–1325
  15. Rodriguez V, Betcher D. 153Sm-EDTMP. J Pediatr Oncol Nurs. 1998;15:95–97
  16. Gaitan-Yanguas M. A study of the response of osteogenic sarcoma and adjacent normal tissue to radiation. Int J Radiat Oncol Biol Phys. 1981;7:593–595
  17. Aas M, Moe L, Gamlem H, Skretting A, Ottesen N, Bruland O. Internal radionuclide therapy of primary osteosarcoma in dogs, using153Sm-EDTMP. Clin Cancer Res. 1999;5:3148s–3152s
  18. Franzius C, Bielack S, Vollet B, Jurgens H, Schober O. High-activity samarium-153 EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin. 1999;38:337–340
  19. Franzius C, Bielack S, Flege S, Eckardt J, Sciuk J, Schober O. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin. 2001;40:215–220
  20. Anderson PM, Wiseman GA, Dispenzieri A, et al. High dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2001;20:189–196
  21. Anderson PM, et al. Gemcitabine radiosensitization after high dose samarium for osteoblastic osteosarcoma. Clin Cancer Res. 2005;11:6895–6900
  22. Anderson PM. Samarium for osteoblastic bone metastasis and osteosarcoma. Expert Opin Pharmacother. 2006;7:1475–1486
  23. Holmes RA. [153Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992;22:41–45
  24. Turner JH, Martindale AA, Sorby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15:784–795
  25. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574–1581
  26. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med. 1994;35:63–69
  27. Probert JC, Parker BR. The effects of radiation therapy on bone growth. Radiology. 1975;114:155–162
  28. Frantz CH. Extreme retardation of epiphyseal growth from roentgen irradiation. Radiology. 1950;55:720–724
  29. Shapiro F. Epiphyseal and physeal cartilage vascularization: a light microscopic and tritiated thymidine autoradiographic study of cartilage canals in newborn and young postnatal rabbit bone. Anat Rec. 1998;252:140–148
  30. Gonzalez DG, Van Dijk DP. Experimental studies on the response of growing bones to x ray and neutron irradiation. Int J Radiat Oncol Biol Phys. 1983;9:671–677
  31. Essman SC, Lewis MR, Miller WH. Intra-organ biodistribution and dosimetry of 153Sm-EDTMP in the juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma. J Nucl Med. 2005;46:2076–2082
  32. Essman SC, Lattimer JC, Cook JL, Turnquist S, Kuroki K. Effects of 153Sm-EDTMP on physeal and articular cartilage in juvenile rabbits. J Nucl Med. 2003;44:1510–1515
  33. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment for metastatic bone cancer. J Nucl Med. 1992;33:1451–1458
  34. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34:1839–1844

PII: S0969-8051(07)00280-6

doi: 10.1016/j.nucmedbio.2007.11.005

Nuclear Medicine and Biology
Volume 35, Issue 2 , Pages 219-225 , February 2008

Article Tools

* Image Usage & Resolution